SG11201502534UA - Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 - Google Patents
Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4Info
- Publication number
- SG11201502534UA SG11201502534UA SG11201502534UA SG11201502534UA SG11201502534UA SG 11201502534U A SG11201502534U A SG 11201502534UA SG 11201502534U A SG11201502534U A SG 11201502534UA SG 11201502534U A SG11201502534U A SG 11201502534UA SG 11201502534U A SG11201502534U A SG 11201502534UA
- Authority
- SG
- Singapore
- Prior art keywords
- her3
- hairpin
- beta
- her4
- antigen binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6817—Toxins
- A61K47/6829—Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12191871 | 2012-11-08 | ||
PCT/EP2013/073093 WO2014072305A1 (en) | 2012-11-08 | 2013-11-06 | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201502534UA true SG11201502534UA (en) | 2015-05-28 |
Family
ID=47143739
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201502534UA SG11201502534UA (en) | 2012-11-08 | 2013-11-06 | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
Country Status (20)
Country | Link |
---|---|
US (2) | US9725511B2 (en) |
EP (1) | EP2917242B1 (en) |
JP (2) | JP6537970B2 (en) |
KR (1) | KR20150063565A (en) |
CN (1) | CN104755499B (en) |
AR (1) | AR093778A1 (en) |
AU (1) | AU2013343666A1 (en) |
CA (1) | CA2884429A1 (en) |
CL (1) | CL2015001230A1 (en) |
CR (1) | CR20150195A (en) |
EA (1) | EA201500503A1 (en) |
HK (1) | HK1211598A1 (en) |
IL (1) | IL237790A0 (en) |
MA (1) | MA38164B1 (en) |
MX (1) | MX2015005756A (en) |
PE (1) | PE20150955A1 (en) |
PH (1) | PH12015500751A1 (en) |
SG (1) | SG11201502534UA (en) |
TW (1) | TWI519542B (en) |
WO (1) | WO2014072305A1 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG11201502534UA (en) * | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
EP2917243B1 (en) * | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
WO2015173248A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Her3/her2 bispecific antibodies binding to the beta-hairpin of her3 and domain ii of her2 |
CA2944895A1 (en) * | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anti-her3 antibodies binding to the beta-hairpin of her3 |
WO2019185164A1 (en) | 2018-03-29 | 2019-10-03 | Hummingbird Bioscience Holdings Pte. Ltd. | Her3 antigen-binding molecules |
CN109022389A (en) * | 2018-07-19 | 2018-12-18 | 陕西慧康生物科技有限责任公司 | A kind of production method of Bacillus coli expression people Iduronate-2-sulfatase |
JPWO2020059772A1 (en) * | 2018-09-20 | 2021-08-30 | 第一三共株式会社 | Treatment of HER3 mutant cancer with anti-HER3 antibody-drug conjugate |
WO2024077122A1 (en) * | 2022-10-05 | 2024-04-11 | The Regents Of The University Of California | Multipurpose, multi-functionalized lipid coated beads and methods of production |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997035885A1 (en) | 1996-03-27 | 1997-10-02 | Genentech, Inc. | ErbB3 ANTIBODIES |
US20020119148A1 (en) * | 2000-09-01 | 2002-08-29 | Gerritsen Mary E. | ErbB4 antagonists |
EP1402041B1 (en) | 2001-06-22 | 2009-10-07 | Roche Diagnostics GmbH | Use of fkbp chaperones as expression tool |
WO2004056855A1 (en) | 2002-12-20 | 2004-07-08 | Roche Diagnostics Gmbh | Soluble complexes of target proteins and peptidyl prolyl isomerase chaperones and methods of making and using them |
WO2003012072A2 (en) * | 2001-08-03 | 2003-02-13 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
AR056857A1 (en) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | DIRECTED ANTIBODIES TO HER-3 (RECEIVER OF THE HUMAN EPIDERMAL GROWTH FACTOR-3) AND ITS USES |
EP1971684B1 (en) * | 2006-01-03 | 2011-10-05 | Roche Diagnostics GmbH | Chimaeric fusion protein with superior chaperone and folding activities |
WO2007115571A2 (en) | 2006-04-07 | 2007-10-18 | Enkam Pharmaceuticals A/S | Erbb receptor-derived peptide fragments |
NZ574093A (en) | 2006-06-12 | 2011-03-31 | Symphogen As | Pan-cell surface receptor- specific therapeutics |
SI2129396T1 (en) | 2007-02-16 | 2013-12-31 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
JP5461423B2 (en) * | 2007-12-13 | 2014-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | Novel rubella E1 envelope protein variant and its use in the detection of anti-rubella antibodies |
TW201544123A (en) | 2009-03-20 | 2015-12-01 | Genentech Inc | Anti-HER antibodies |
MX2011010166A (en) | 2009-04-07 | 2011-10-11 | Roche Glycart Ag | Bispecific anti-erbb-3/anti-c-met antibodies. |
WO2010127181A1 (en) | 2009-04-29 | 2010-11-04 | Trellis Bioscience, Inc. | Improved antibodies immunoreactive with heregulin-coupled her3 |
EP3546483A1 (en) | 2010-05-20 | 2019-10-02 | Ablynx N.V. | Biological materials related to her3 |
SI2606070T1 (en) * | 2010-08-20 | 2017-04-26 | Novartis Ag | Antibodies for epidermal growth factor receptor 3 (her3) |
TW201302793A (en) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | Novel antigen binding proteins |
EA201490180A1 (en) | 2011-06-30 | 2014-08-29 | Мерримак Фармасьютикалз, Инк. | ANTIBODIES TO ERBB3 IN COMBINATION WITH PAKLITAXEL FOR THE TREATMENT OF GYNECOLOGICAL MALIGNANT DISEASES |
AU2012316402B2 (en) | 2011-09-30 | 2017-04-20 | Regeneron Pharmaceuticals, Inc. | Anti-ErbB3 antibodies and uses thereof |
EA202092280A3 (en) | 2011-12-05 | 2021-09-30 | Новартис Аг | ANTIBODIES TO EPIDERMAL GROWTH FACTOR 3 (HER3) RECEPTOR |
IN2014CN04373A (en) | 2011-12-05 | 2015-09-04 | Novartis Ag | |
EP2917243B1 (en) * | 2012-11-08 | 2018-03-14 | F.Hoffmann-La Roche Ag | Her3 antigen binding proteins binding to the beta-hairpin of her3 |
SG11201502534UA (en) * | 2012-11-08 | 2015-05-28 | Hoffmann La Roche | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 |
CA2944895A1 (en) | 2014-05-14 | 2015-11-19 | F. Hoffmann-La Roche Ag | Anti-her3 antibodies binding to the beta-hairpin of her3 |
-
2013
- 2013-11-06 SG SG11201502534UA patent/SG11201502534UA/en unknown
- 2013-11-06 CA CA2884429A patent/CA2884429A1/en not_active Abandoned
- 2013-11-06 EP EP13789759.1A patent/EP2917242B1/en active Active
- 2013-11-06 CN CN201380056465.2A patent/CN104755499B/en active Active
- 2013-11-06 US US14/073,137 patent/US9725511B2/en active Active
- 2013-11-06 PE PE2015000609A patent/PE20150955A1/en not_active Application Discontinuation
- 2013-11-06 AU AU2013343666A patent/AU2013343666A1/en not_active Abandoned
- 2013-11-06 WO PCT/EP2013/073093 patent/WO2014072305A1/en active Application Filing
- 2013-11-06 MA MA38164A patent/MA38164B1/en unknown
- 2013-11-06 KR KR1020157011989A patent/KR20150063565A/en not_active Application Discontinuation
- 2013-11-06 JP JP2015540165A patent/JP6537970B2/en not_active Expired - Fee Related
- 2013-11-06 EA EA201500503A patent/EA201500503A1/en unknown
- 2013-11-06 AR ARP130104061A patent/AR093778A1/en unknown
- 2013-11-06 MX MX2015005756A patent/MX2015005756A/en unknown
- 2013-11-07 TW TW102140562A patent/TWI519542B/en not_active IP Right Cessation
-
2015
- 2015-03-16 IL IL237790A patent/IL237790A0/en unknown
- 2015-04-06 PH PH12015500751A patent/PH12015500751A1/en unknown
- 2015-04-16 CR CR20150195A patent/CR20150195A/en unknown
- 2015-05-07 CL CL2015001230A patent/CL2015001230A1/en unknown
- 2015-12-11 HK HK15112242.4A patent/HK1211598A1/en unknown
-
2017
- 2017-08-03 US US15/668,396 patent/US10364290B2/en not_active Expired - Fee Related
- 2017-11-06 JP JP2017213776A patent/JP2018068298A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US10364290B2 (en) | 2019-07-30 |
CR20150195A (en) | 2015-05-18 |
JP2015536336A (en) | 2015-12-21 |
KR20150063565A (en) | 2015-06-09 |
CA2884429A1 (en) | 2014-05-15 |
WO2014072305A1 (en) | 2014-05-15 |
CN104755499A (en) | 2015-07-01 |
HK1211598A1 (en) | 2016-05-27 |
JP2018068298A (en) | 2018-05-10 |
MX2015005756A (en) | 2015-09-16 |
AU2013343666A1 (en) | 2015-04-09 |
EP2917242A1 (en) | 2015-09-16 |
US20140186354A1 (en) | 2014-07-03 |
AR093778A1 (en) | 2015-06-24 |
TW201422641A (en) | 2014-06-16 |
TWI519542B (en) | 2016-02-01 |
EA201500503A1 (en) | 2015-10-30 |
MA38164A3 (en) | 2018-05-31 |
CL2015001230A1 (en) | 2015-07-10 |
JP6537970B2 (en) | 2019-07-03 |
EP2917242B1 (en) | 2018-05-16 |
MA38164B1 (en) | 2018-11-30 |
CN104755499B (en) | 2020-10-02 |
IL237790A0 (en) | 2015-05-31 |
PE20150955A1 (en) | 2015-06-20 |
US20180118837A1 (en) | 2018-05-03 |
PH12015500751A1 (en) | 2015-05-25 |
US9725511B2 (en) | 2017-08-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1211598A1 (en) | Anti-her3/her4 antigen binding proteins binding to the beta-hairpin of her3 and the beta-hairpin of her4 her3- her4- her3/her4 | |
HK1216257A1 (en) | Prolactin receptor binding proteins and uses thereof | |
EP2788377A4 (en) | Her3 antibodies and uses thereof | |
HK1211597A1 (en) | Her3 antigen binding proteins binding to the beta-hairpin of her3 her3- her3 | |
HK1209779A1 (en) | Transposition-mediated identification of specific binding or functional proteins | |
HK1203207A1 (en) | Binding molecules specific for her3 and uses thereof her3 | |
HK1211955A1 (en) | Antibodies to aripiprazole haptens and use thereof | |
EP2867259A4 (en) | Novel monoclonal antibody binding specifically to dll4 and use thereof | |
HK1208236A1 (en) | Antigen binding proteins that bind ccr2 ccr2 | |
HUE042531T2 (en) | Anti-asic1 antibodies and uses thereof | |
EP2861623A4 (en) | Novel antibody specific for clec14a and uses thereof | |
HK1208474A1 (en) | Antigen binding proteins that bind egfr egfr | |
HK1214283A1 (en) | Antigen binding proteins that bind erbb3 erbb3 | |
HRP20150468T1 (en) | Antibodies that bind tgf-alpha and epiregulin | |
HK1218921A1 (en) | Antibodies specifically binding to her3 her3 | |
EP2886556A4 (en) | Novel monoclonal antibody which is specifically bound to tm4sf5 protein and use thereof |